ProVise Management Group LLC Buys 30,057 Shares of Medtronic PLC $MDT

ProVise Management Group LLC grew its stake in Medtronic PLC (NYSE:MDT) by 19.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,745 shares of the medical technology company’s stock after acquiring an additional 30,057 shares during the quarter. Medtronic comprises about 1.3% of ProVise Management Group LLC’s portfolio, making the stock its 23rd biggest position. ProVise Management Group LLC’s holdings in Medtronic were worth $17,500,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Artisan Partners Limited Partnership boosted its stake in Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after acquiring an additional 31,314 shares in the last quarter. AXQ Capital LP increased its position in shares of Medtronic by 25.6% during the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares in the last quarter. UMB Bank n.a. increased its position in shares of Medtronic by 65.8% during the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after purchasing an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC purchased a new stake in shares of Medtronic during the 3rd quarter valued at $1,308,000. Finally, Willis Investment Counsel lifted its holdings in shares of Medtronic by 5.0% during the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after purchasing an additional 19,192 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT stock opened at $90.83 on Monday. The firm has a market capitalization of $116.61 billion, a price-to-earnings ratio of 25.30, a price-to-earnings-growth ratio of 2.28 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business has a fifty day moving average of $98.69 and a 200 day moving average of $97.02. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s payout ratio is 79.11%.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved quarterly cash dividend of $0.71 per share (annualized yield ~3.1%), supporting income investors and signaling confidence in cash flow. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Product/market progress in diabetes care with the MiniMed Go Smart MDI system launch in Europe, strengthening Medtronic’s connected diabetes portfolio and long‑term growth potential in CGM/smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Operational tech wins: updates on a Tempus clinical trial and expanded patient‑monitoring alliance with GE HealthCare, which could broaden distribution and adoption of Medtronic devices over time. Digital Alerts and Heart Valves: What Medtronic Investors Should Watch in New Tempus Trial Medtronic, GE HealthCare expand patient monitoring alliance
• Neutral Sentiment: MiniMed priced its IPO at $20 per share and raised about $560M, giving the standalone diabetes unit initial capital and a public valuation backdrop. This is a financing/structuring move that could be positive long term but is mixed near term. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO
• Negative Sentiment: MiniMed’s Nasdaq debut opened below the offering price (shares down ~4.8% on debut), which pressured sentiment toward the spinoff and Medtronic’s value‑unlock story — investors reacted to a softer than expected market reception. Medtronic’s diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
• Negative Sentiment: Medtronic retains ~90% ownership of MiniMed after the IPO, limiting immediate capital release and potential near‑term accretion from the spinoff — this reduces the perceived benefit of the listing for MDT shareholders today. MiniMed (MMED) IPO Falls Flat as Medtronic (MDT) Spinoff Debuts Below Price

Wall Street Analysts Forecast Growth

MDT has been the topic of several research analyst reports. Citigroup started coverage on Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price on the stock. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Wells Fargo & Company assumed coverage on Medtronic in a report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target for the company. Barclays restated an “overweight” rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday, February 18th. Finally, Sanford C. Bernstein upped their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).